Natera ( (NTRA) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Natera’s stock has experienced unusual movements following the company’s announcement of successfully enrolling over 1,600 patients in the EXPAND trial. Additionally, a study published in the Journal of Clinical Oncology highlighted the potential of Signatera as a prognostic biomarker for germ cell tumors, sparking increased interest. As a result, analysts have raised the company’s price target, driven by the promising trial results and the validation study of Signatera.
More about Natera
YTD Price Performance: 0.23%
Average Trading Volume: 1,266,129
Technical Sentiment Signal: Strong Buy
Current Market Cap: $22.38B
For further insights into NTRA stock on TipRanks’ Stock Analysis page.
See more of today’s top stock gainers and losers.